DDX3-IN-2 is an active DEADbox polypeptide 3 ( DDX3 ) inhibitor with an IC 50 value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome HIV resistance In Vitro DDX3-IN-2 behaves as a competitive inhibitor with respect to the RNA substrate, which can be seen by the decrease in its inhibition potency as a function of increasing RNA substrate concentrations. DDX3-IN-2 is found to be completely inactive against the ATPase of DDX3, DDX1 helicase, and DENV NS3 helicase. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo DDX3-IN-2 (20 mg/kg; tail vein injection) possesses excellent biocompatibility, and Wistar rats shows a good tolerance to the dose of 20 mg/kg . DDX3-IN-2 (10 mg/kg; i.v. bolus injection; 0~25 hours) rapidly eliminates the half-life elimination and the plasmatic clearance values . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Wistar rats Dosage: Tail vein injection Administration: 20 mg/kg Result: Possessed excellent biocompatibility, and Wistar rats showed a good tolerance to the dose of 20 mg/kg. Animal Model: Rats Dosage: I.v. bolus injection (Pharmacokinetic Analysis) Administration: 10 mg/kg; 0~25 hours Result: Rapidly eliminated the half-life elimination and the plasmatic clearance values. Form:Solid IC50& Target:HIV